UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E134-E134

2016

Volltextzugriff (PDF)

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

The New England journal of medicine, 2022-10, Vol.387 (17), p.1557-1568

2022

Volltextzugriff (PDF)

1024MO Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy

Annals of oncology, 2023-10, Vol.34, p.S623-S623

2023

Volltextzugriff (PDF)

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Annals of oncology, 2019-04, Vol.30 (4), p.589-596

2019

Volltextzugriff (PDF)

1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses

Annals of oncology, 2024-09, Vol.35, p.S722-S722

2024

Volltextzugriff (PDF)

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Annals of oncology, 2024-09, Vol.35, p.S723-S724

2024

Volltextzugriff (PDF)

1088MO A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

Annals of oncology, 2023-10, Vol.34, p.S655-S655

2023

Volltextzugriff (PDF)

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

Annals of oncology, 2023-10, Vol.34, p.S664-S665

2023

Volltextzugriff (PDF)

1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma

Annals of oncology, 2024-09, Vol.35, p.S732-S733

2024

Volltextzugriff (PDF)

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

Annals of oncology, 2024-09, Vol.35, p.S730-S731

2024

Volltextzugriff (PDF)

789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study

Annals of oncology, 2022-09, Vol.33, p.S904-S905

2022

Volltextzugriff (PDF)

817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

Annals of oncology, 2022-09, Vol.33, p.S920-S921

2022

Volltextzugriff (PDF)

LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047

Annals of oncology, 2023-10, Vol.34, p.S1290-S1291

2023

Volltextzugriff (PDF)

1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047

Annals of oncology, 2021-09, Vol.32, p.S867-S868

2021

Volltextzugriff (PDF)

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

Annals of oncology, 2018-10, Vol.29, p.viii464-viii465

2018

Volltextzugriff (PDF)

781 Melanoma subtypes demonstrate distinct PD-L1 expression profiles

Journal of investigative dermatology, 2017-05, Vol.137 (5), p.S134-S134

2017

Volltextzugriff (PDF)

33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

Immuno-oncology technology, 2023-12, Vol.20, p.100502, Article 100502

2023

Volltextzugriff (PDF)

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : résultats à 2 ans de RELATIVITY-047

Annales de Dermatologie et de Vénéréologie - FMC, 2023-12, Vol.3 (8), p.A351-A353

2023

Volltextzugriff (PDF)

NIVO + RELA vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : survie globale et taux de réponse objective par sous-groupes clés de l’étude RELATIVITY-047

Annales de Dermatologie et de Vénéréologie - FMC, 2022-11, Vol.2 (8), p.A95-A96

2022

Volltextzugriff (PDF)

Frequency-dependent distortions of composite triple beat in lightwave CATV transmission systems

IEEE journal on selected areas in communications, 1990-09, Vol.8 (7), p.1365-1368

1990

Volltextzugriff (PDF)

High-fidelity lightwave transmission of multiple AM-VSB NTSC signals

IEEE transactions on microwave theory and techniques, 1990-05, Vol.38 (5), p.483-493

1990

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(19)
Französisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 7 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

1024MO Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

1088MO A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study

817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047

1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

781 Melanoma subtypes demonstrate distinct PD-L1 expression profiles

33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : résultats à 2 ans de RELATIVITY-047

NIVO + RELA vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : survie globale et taux de réponse objective par sous-groupes clés de l’étude RELATIVITY-047

Frequency-dependent distortions of composite triple beat in lightwave CATV transmission systems

High-fidelity lightwave transmission of multiple AM-VSB NTSC signals

Suchergebnisse filtern